Claims for Patent: 9,803,019

Summary for Patent: 9,803,019

Title:	Carrier immunoglobulins and uses thereof
Abstract:	Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
Inventor(s):	Walker; Kenneth W. (Newbury Park, CA), Jacobsen; Frederick W. (Newbury Park, CA), Arora; Taruna (Palo Alto, CA)
Assignee:	AMGEN INC. (Thousand Oaks, CA)
Application Number:	14/627,992
Patent Claims:	1. An isolated immunoglobulin, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein: (a) the light chain variable region comprises the amino acid sequence of SEQ ID NO:196 and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:335, SEQ ID NO:349, SEQ ID NO:351, SEQ ID NO:353, SEQ ID NO:355, or SEQ ID NO:359, or (b) the light chain variable region comprises the amino acid sequence of SEQ ID NO:204 and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:349 or SEQ ID NO:355, or (c) the light chain variable region comprises the amino acid sequence of SEQ ID NO:202 and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:349, or (d) the light chain variable region comprises the amino acid sequence of SEQ ID NO:192 and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:357, SEQ ID NO:359, or SEQ ID NO:369, or (e) the light chain variable region comprises the amino acid sequence of SEQ ID NO:194 and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:335, SEQ ID NO:349, or SEQ ID NO:351. 2. The isolated immunoglobulin of claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:196; and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:353. 3. The isolated immunoglobulin of claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:202; and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:349. 4. The isolated immunoglobulin of claim 1, wherein the isolated immunoglobulin is an antibody. 5. The isolated immunoglobulin of claim 4, wherein the antibody is an IgG1, IgG2, IgG3 or IgG4 antibody. 6. The isolated immunoglobulin of claim 4, wherein the antibody is a monoclonal antibody. 7. The isolated immunoglobulin of claim 6, wherein the monoclonal antibody is a human antibody. 8. The isolated immunoglobulin of claim 7, comprising: (a) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:101, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminus or C-terminus, or both; and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:98, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminus or C-terminus, or both; or (b) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:119, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminus or C-terminus, or both; and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:116, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminus or C-terminus, or both. 9. The isolated immunoglobulin of claim 1, further comprising at least one pharmacologically active chemical moiety conjugated thereto. 10. The isolated immunoglobulin of claim 9, wherein the pharmacologically active chemical moiety is a pharmacologically active polypeptide. 11. The isolated immunoglobulin of claim 10, wherein the immunoglobulin is recombinantly produced. 12. The isolated immunoglobulin of claim 11, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is inserted in the primary amino acid sequence of the immunoglobulin heavy chain within an internal loop of the Fc domain of the immunoglobulin heavy chain. 13. The isolated immunoglobulin of claim 10, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is conjugated at the N-terminus or C-terminus of the immunoglobulin heavy chain. 14. The isolated immunoglobulin of claim 10, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is conjugated at the N-terminus or C-terminus of the immunoglobulin light chain. 15. The isolated immunoglobulin of claim 10, wherein the pharmacologically active polypeptide is a toxin peptide or peptide analog, an IL-6 binding peptide, a calcitonin gene-related peptide (CGRP) peptide antagonist, a bradykinin B1 receptor peptide antagonist, a parathyroid hormone (PTH) agonist peptide, a PTH antagonist peptide, an angiopoietin-1 (ang-1) binding peptide, an angiopoietin-2 (ang-2) binding peptide, a myostatin binding peptide, an erythropoietin (EPO)-mimetic peptide, a fibroblast growth factor 21 (FGF21) peptide, a thrombopoietin (TPO)-mimetic peptide, a nerve growth factor (NGF) binding peptide, a B-cell activating factor (BAFF) antagonist peptide, a glucagon-like peptide-1 (GLP-1) or peptide mimetic thereof, or a glucagon-like peptide-2 (GLP-2) or peptide mimetic thereof. 16. The isolated immunoglobulin of claim 15, wherein the toxin peptide or peptide analog is stichodactyla toxin (ShK) or a ShK peptide analog. 17. A pharmaceutical composition comprising the immunoglobulin of claim 1 and a pharmaceutically acceptable diluent, excipient or carrier. 18. The immunoglobulin of claim 1, wherein the immunoglobulin at 10 micromolar concentration does not significantly bind soluble human TR2 (SEQ ID NO:82) at 10 nanomolar concentration in an aqueous solution incubated under physiological conditions, as measured by a surface plasmon resonance binding assay. 19. The isolated immunoglobulin of claim 10, wherein the pharmacologically active polypeptide is conjugated to the immunoglobulin via a functional group on a side chain of an amino acid residue within the primary sequence of the immunoglobulin. 20. The isolated immunoglobulin of claim 10, wherein the pharmacologically active polypeptide is conjugated to the immunoglobulin via a non-peptidyl or peptidyl linker. 21. The isolated immunoglobulin of claim 20, wherein the peptidyl linker comprises glycine, serine, alanine, or combinations thereof. 22. The isolated immunoglobulin of claim 20, wherein the non-peptidyl linker is a polyethylene glycol linker. 23. The isolated immunoglobulin of claim 15, wherein the pharmacologically active polypeptide is a toxin peptide or peptide analog. 24. The isolated immunoglobulin of claim 1, wherein the isolated immunoglobulin is an antibody fragment selected from a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a single-chain Fv (scFv) fragment, or a Fd fragment. 25. The isolated immunoglobulin of claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:204; and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:349. 26. The isolated immunoglobulin of claim 1, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:204; and the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:355.

Details for Patent 9,803,019

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-09-22